ASCO Guidelines for the Use of CA 27‑29 in Metastatic Breast Cancer
Regulatory Approval
- The U.S. Food and Drug Administration has approved the CA 27‑29 blood assay specifically for monitoring disease activity in patients with known metastatic breast cancer who are receiving active therapy【1】.
Recommended Clinical Use (ASCO)
- The American Society of Clinical Oncology (ASCO) recommends using CA 27‑29 only to monitor patients with metastatic breast cancer during active treatment, and only when the result is interpreted together with imaging studies, clinical history, and physical examination—not as a stand‑alone test【1】.
Timing Considerations
- CA 27‑29 results obtained within the first 4–6 weeks after initiating a new therapy should not be interpreted, because transient, non‑reflective rises are common during this early period【2】.
Indications Explicitly Not Recommended (ASCO)
- Screening asymptomatic individuals for breast cancer – the test lacks sufficient sensitivity and specificity【1】.
- Diagnosis of breast cancer – CA 27‑29 cannot establish a cancer diagnosis【3】.
- Initial staging at diagnosis – the assay does not aid treatment decisions in early‑stage disease【3】.
- Routine surveillance after primary treatment to detect recurrence – although CA 27‑29 may identify recurrence 5–6 months earlier, there is no evidence that this improves overall survival, quality of life, or cost‑effectiveness【1】【3】.
Common Ordering Errors (ASCO)
Ordering CA 27‑29 for post‑surgical follow‑up is not evidence‑based and can cause unnecessary anxiety without a demonstrated survival benefit【1】.
Any rise in CA 27‑29 should be confirmed with appropriate imaging before any change in therapy is made【1】.
CA 27.29 in Breast Cancer Management
Introduction to CA 27.29
- The American Society of Clinical Oncology recommends against using CA 27.29 for screening, diagnosis, staging, or routine surveillance after primary treatment, as it has limited clinical utility in these areas, and its primary use is in monitoring metastatic disease during active therapy 4, 5
Clinical Utility of CA 27.29
- CA 27.29 is elevated in approximately 81% of metastatic breast cancer cases, and can be used alongside imaging and clinical assessment to monitor disease progression 6
- The American Society of Clinical Oncology recommends using CA 27.29 to monitor metastatic disease during active therapy, but not as a standalone test 4, 5
Interpreting CA 27.29 Results
- A median CA 27.29 increase of 32% indicates progressive disease, while a median decrease of 19% indicates stable or regressing disease 6
- A rising CA 27.29 level of ≥20% suggests treatment failure, particularly when measurable disease is absent 6, 5
Timing of CA 27.29 Interpretation
- CA 27.29 levels should not be interpreted during the first 4-6 weeks of new therapy, as spurious early rises can occur 4, 5